Complimentary U.S. shipping on orders over $250 American-manufactured Independently verified Documentation on request

The Post-Peptide-Sciences Landscape: Where Research Labs Are Sourcing Now

With Peptide Sciences gone, the U.S. research-peptide market reshuffled. An analysis of where the category is heading in 2026 and what research chemists should evaluate in a replacement supplier.

The closure of Peptide Sciences left a measurable gap in the U.S. research-peptide supply chain. This article is a chemistry-first analysis of that gap and the criteria serious research labs are applying to its successors.

The Shape of the Gap

Peptide Sciences’ former market share concentrated on a specific kind of buyer: U.S.-based research labs, independent chemists, and educational institutions who needed documented reference standards rather than consumer-grade repackaged peptides. When that supply channel closed, three outcomes followed:

  1. Downstream consolidation. Research chemists migrated toward adjacent U.S. catalogs — often with rushed supplier vetting and inconsistent COA rigor.
  2. Price volatility. Several mid-tier catalogs raised prices 20–35% on BPC-157, TB-500, and GH-axis SKUs in the first two quarters post-closure.
  3. Grey-market expansion. Overseas resellers with minimal documentation filled search queries, especially in non-English-speaking channels.

For research labs, outcome three is the operational risk — a compound with a generic “COA” and no traceable lot chain is not a reference standard.

What Serious Labs Evaluate Now

In our conversations with returning research customers, the decision criteria have shifted. Five requirements dominate:

  1. Domestic synthesis. Not domestic repacking of overseas material. A U.S. supplier that ships from a U.S. warehouse but sources from an overseas manufacturer isn’t actually domestic. Look for the synthesis facility address.
  2. Per-lot published COAs. The COA must match the lot number on the vial, and ideally be reviewable before purchase.
  3. ISO 9001 or equivalent documentation framework. This is an administrative bar, not a chemistry bar, but it indicates the supplier has defined procedures for deviation reporting.
  4. Dedicated research-only compliance framing. Suppliers who cross the line into consumer marketing, human-outcome framing, or dosing advice are category-exit risks.
  5. Known ownership and contact channel. Not an anonymous domain with a Gmail address.

Where BioFusion Aminos Sits

BioFusion Aminos was built specifically to fit all five. Every compound is synthesized in the United States at facilities operating under an ISO 9001:2008 documentation framework. Every lot publishes a batch-specific Certificate of Analysis in the public COA library — reviewable pre-purchase. Every product is marketed as a research reference standard, with no consumer framing, no human outcome language, and no dosing guidance.

In chemistry terms, the catalog now covers:

The Competitive Set, Briefly

Several catalogs are viable replacements on specific SKUs. The honest answer: the U.S. peptide reference market is fragmenting into two tiers — one where chemistry quality, COA discipline, and compliance framing are all handled, and one where they are not. Our recommendation: compare COAs side-by-side before migrating a lab’s standing reorder pattern. Chemistry quality isn’t a branding question.

What to Ask Any New Supplier

  1. Where is the synthesis performed?
  2. Is the COA batch-specific or SKU-generic?
  3. Is the COA published pre-purchase or emailed on request?
  4. What is the endotoxin, moisture, and counterion result on my next order’s lot?
  5. What is the turnaround if a lot fails internal verification?

If any answer is unclear, the supplier probably isn’t set up for research-grade reproducibility.

Related Reading

Laboratory research use only. This article analyzes the research-chemistry supply chain and is not a product recommendation for non-research use.